Seaside Therapeutics has revealed its second failed study for its lead drug STX209 this month. In one of two Phase III studies for the compound for the genetic mental disorder Fragile X syndrome, STX209 treatment missed its main goal of reducing social withdrawal.
Cancer vaccines have so far generated more headlines than health benefits. Even some of the success stories, like Dendreon, have faltered once faced with trying to commercialize an oncology immunotherapy. Yet the vast potential means people continue to talk up the sector.
The U.K.'s cost-effectiveness police have been arresting Roche's Avastin development efforts once again. As Cover magazine reports, the National Institute for Health and Clinical Excellence has nixed two proposed uses for the drug in ovarian cancer, one of the hardest-to-treat forms of the disease.
Roche may be trying to unload its blood glucose meter business, reflecting continued challenges over reimbursement, and a contrast from the far better success the company has enjoyed with diagnostics development.
Roche got a big boost for its bid to position the leukemia drug GA101 (obinutuzumab) as a next-gen successor to its blockbuster Rituxan, posting late-stage data last night that showed that a combination with chemotherapy performed much better than chemo alone or in combination with Rituxan.
Before the massive ASCO meeting kicks off on May 31, the Swiss drug giant plans to unveil data from a late-stage study of its next-gen antibody GA101, which is heir to the throne occupied by the company and partner Biogen Idec's Rituxan.
Along with its partner, Astellas, Roche has won FDA approval for a new, first-line use for its lung cancer drug Tarceva in patients whose cancers test positive for specific mutations of the EGFR gene. Roche also got the nod for a diagnostic test to identify eligible patients.
Regeneron Pharmaceuticals is like a sports team on a streak that keeps bettors in the money by beating bookmaker odds time and again. This streak has gone uninterrupted for nearly two years.
Seaside Therapeutics missed the main target of a midstage trial of its lead drug STX209 in patients with autism spectrum disorder (ASD), yet benefits of treatment observed in the Phase IIb study have driven the company to plan another major clinical trial in patients with the intellectual disorder.
The FDA has been fighting assaults on the pharma supply chain on two major fronts: outright counterfeits and foreign-made versions of drugs. Now a hybrid has appeared: an unapproved, foreign version of Allergan's cosmetic treatment Botox in counterfeit packaging